Cargando…

Combined Multiomics and In Silico Approach Uncovers PRKAR1A as a Putative Therapeutic Target in Multi-Organ Dysfunction Syndrome

[Image: see text] Despite all epidemiological, clinical, and experimental research efforts, therapeutic concepts in sepsis and sepsis-induced multi-organ dysfunction syndrome (MODS) remain limited and unsatisfactory. Currently, gene expression data sets are widely utilized to discover new biomarkers...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Prithvi, Mohsin, Mohd, Sultan, Armiya, Jha, Prakash, Khan, Mohd Mabood, Syed, Mansoor Ali, Chopra, Madhu, Serajuddin, Mohammad, Rahmani, Arshad Husain, Almatroodi, Saleh A., Alrumaihi, Faris, Dohare, Ravins
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018728/
https://www.ncbi.nlm.nih.gov/pubmed/36936296
http://dx.doi.org/10.1021/acsomega.3c00020
_version_ 1784907874712944640
author Singh, Prithvi
Mohsin, Mohd
Sultan, Armiya
Jha, Prakash
Khan, Mohd Mabood
Syed, Mansoor Ali
Chopra, Madhu
Serajuddin, Mohammad
Rahmani, Arshad Husain
Almatroodi, Saleh A.
Alrumaihi, Faris
Dohare, Ravins
author_facet Singh, Prithvi
Mohsin, Mohd
Sultan, Armiya
Jha, Prakash
Khan, Mohd Mabood
Syed, Mansoor Ali
Chopra, Madhu
Serajuddin, Mohammad
Rahmani, Arshad Husain
Almatroodi, Saleh A.
Alrumaihi, Faris
Dohare, Ravins
author_sort Singh, Prithvi
collection PubMed
description [Image: see text] Despite all epidemiological, clinical, and experimental research efforts, therapeutic concepts in sepsis and sepsis-induced multi-organ dysfunction syndrome (MODS) remain limited and unsatisfactory. Currently, gene expression data sets are widely utilized to discover new biomarkers and therapeutic targets in diseases. In the present study, we analyzed MODS expression profiles (comprising 13 sepsis and 8 control samples) retrieved from NCBI-GEO and found 359 differentially expressed genes (DEGs), among which 170 were downregulated and 189 were upregulated. Next, we employed the weighted gene co-expression network analysis (WGCNA) to establish a MODS-associated gene co-expression network (weighted) and identified representative module genes having an elevated correlation with age. Based on the results, a turquoise module was picked as our hub module. Further, we constructed the PPI network comprising 35 hub module DEGs. The DEGs involved in the highest-confidence PPI network were utilized for collecting pathway and gene ontology (GO) terms using various libraries. Nucleotide di- and triphosphate biosynthesis and interconversion was the most significant pathway. Also, 3 DEGs within our PPI network were involved in the top 5 significantly enriched ontology terms, with hypercortisolism being the most significant term. PRKAR1A was the overlapping gene between top 5 significant pathways and GO terms, respectively. PRKAR1A was considered as a therapeutic target in MODS, and 2992 ligands were screened for binding with PRKAR1A. Among these ligands, 3 molecules based on CDOCKER score (molecular dynamics simulated-based score, which allows us to rank the binding poses according to their quality and to identify the best pose for each system) and crucial interaction with human PRKAR1A coding protein and protein kinase-cyclic nucleotide binding domains (PKA RI alpha CNB-B domain) via active site binding residues, viz. Val283, Val302, Gln304, Val315, Ile327, Ala336, Ala337, Val339, Tyr373, and Asn374, were considered as lead molecules.
format Online
Article
Text
id pubmed-10018728
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-100187282023-03-17 Combined Multiomics and In Silico Approach Uncovers PRKAR1A as a Putative Therapeutic Target in Multi-Organ Dysfunction Syndrome Singh, Prithvi Mohsin, Mohd Sultan, Armiya Jha, Prakash Khan, Mohd Mabood Syed, Mansoor Ali Chopra, Madhu Serajuddin, Mohammad Rahmani, Arshad Husain Almatroodi, Saleh A. Alrumaihi, Faris Dohare, Ravins ACS Omega [Image: see text] Despite all epidemiological, clinical, and experimental research efforts, therapeutic concepts in sepsis and sepsis-induced multi-organ dysfunction syndrome (MODS) remain limited and unsatisfactory. Currently, gene expression data sets are widely utilized to discover new biomarkers and therapeutic targets in diseases. In the present study, we analyzed MODS expression profiles (comprising 13 sepsis and 8 control samples) retrieved from NCBI-GEO and found 359 differentially expressed genes (DEGs), among which 170 were downregulated and 189 were upregulated. Next, we employed the weighted gene co-expression network analysis (WGCNA) to establish a MODS-associated gene co-expression network (weighted) and identified representative module genes having an elevated correlation with age. Based on the results, a turquoise module was picked as our hub module. Further, we constructed the PPI network comprising 35 hub module DEGs. The DEGs involved in the highest-confidence PPI network were utilized for collecting pathway and gene ontology (GO) terms using various libraries. Nucleotide di- and triphosphate biosynthesis and interconversion was the most significant pathway. Also, 3 DEGs within our PPI network were involved in the top 5 significantly enriched ontology terms, with hypercortisolism being the most significant term. PRKAR1A was the overlapping gene between top 5 significant pathways and GO terms, respectively. PRKAR1A was considered as a therapeutic target in MODS, and 2992 ligands were screened for binding with PRKAR1A. Among these ligands, 3 molecules based on CDOCKER score (molecular dynamics simulated-based score, which allows us to rank the binding poses according to their quality and to identify the best pose for each system) and crucial interaction with human PRKAR1A coding protein and protein kinase-cyclic nucleotide binding domains (PKA RI alpha CNB-B domain) via active site binding residues, viz. Val283, Val302, Gln304, Val315, Ile327, Ala336, Ala337, Val339, Tyr373, and Asn374, were considered as lead molecules. American Chemical Society 2023-03-01 /pmc/articles/PMC10018728/ /pubmed/36936296 http://dx.doi.org/10.1021/acsomega.3c00020 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Singh, Prithvi
Mohsin, Mohd
Sultan, Armiya
Jha, Prakash
Khan, Mohd Mabood
Syed, Mansoor Ali
Chopra, Madhu
Serajuddin, Mohammad
Rahmani, Arshad Husain
Almatroodi, Saleh A.
Alrumaihi, Faris
Dohare, Ravins
Combined Multiomics and In Silico Approach Uncovers PRKAR1A as a Putative Therapeutic Target in Multi-Organ Dysfunction Syndrome
title Combined Multiomics and In Silico Approach Uncovers PRKAR1A as a Putative Therapeutic Target in Multi-Organ Dysfunction Syndrome
title_full Combined Multiomics and In Silico Approach Uncovers PRKAR1A as a Putative Therapeutic Target in Multi-Organ Dysfunction Syndrome
title_fullStr Combined Multiomics and In Silico Approach Uncovers PRKAR1A as a Putative Therapeutic Target in Multi-Organ Dysfunction Syndrome
title_full_unstemmed Combined Multiomics and In Silico Approach Uncovers PRKAR1A as a Putative Therapeutic Target in Multi-Organ Dysfunction Syndrome
title_short Combined Multiomics and In Silico Approach Uncovers PRKAR1A as a Putative Therapeutic Target in Multi-Organ Dysfunction Syndrome
title_sort combined multiomics and in silico approach uncovers prkar1a as a putative therapeutic target in multi-organ dysfunction syndrome
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018728/
https://www.ncbi.nlm.nih.gov/pubmed/36936296
http://dx.doi.org/10.1021/acsomega.3c00020
work_keys_str_mv AT singhprithvi combinedmultiomicsandinsilicoapproachuncoversprkar1aasaputativetherapeutictargetinmultiorgandysfunctionsyndrome
AT mohsinmohd combinedmultiomicsandinsilicoapproachuncoversprkar1aasaputativetherapeutictargetinmultiorgandysfunctionsyndrome
AT sultanarmiya combinedmultiomicsandinsilicoapproachuncoversprkar1aasaputativetherapeutictargetinmultiorgandysfunctionsyndrome
AT jhaprakash combinedmultiomicsandinsilicoapproachuncoversprkar1aasaputativetherapeutictargetinmultiorgandysfunctionsyndrome
AT khanmohdmabood combinedmultiomicsandinsilicoapproachuncoversprkar1aasaputativetherapeutictargetinmultiorgandysfunctionsyndrome
AT syedmansoorali combinedmultiomicsandinsilicoapproachuncoversprkar1aasaputativetherapeutictargetinmultiorgandysfunctionsyndrome
AT chopramadhu combinedmultiomicsandinsilicoapproachuncoversprkar1aasaputativetherapeutictargetinmultiorgandysfunctionsyndrome
AT serajuddinmohammad combinedmultiomicsandinsilicoapproachuncoversprkar1aasaputativetherapeutictargetinmultiorgandysfunctionsyndrome
AT rahmaniarshadhusain combinedmultiomicsandinsilicoapproachuncoversprkar1aasaputativetherapeutictargetinmultiorgandysfunctionsyndrome
AT almatroodisaleha combinedmultiomicsandinsilicoapproachuncoversprkar1aasaputativetherapeutictargetinmultiorgandysfunctionsyndrome
AT alrumaihifaris combinedmultiomicsandinsilicoapproachuncoversprkar1aasaputativetherapeutictargetinmultiorgandysfunctionsyndrome
AT dohareravins combinedmultiomicsandinsilicoapproachuncoversprkar1aasaputativetherapeutictargetinmultiorgandysfunctionsyndrome